Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Steven Hoerter | M | 53 | 6 years | |
| Ron Squarer | M | 57 | 5 years | |
| Edward Benz | M | 78 | 5 years | |
| Susan Kelley | M | 69 | 5 years | |
| Franklin Friedman | M | 66 | 5 years | |
| Matthew Sherman | M | 68 | 5 years | |
| Jeff Held | M | 55 | 6 years | |
| Daniel Martin | M | 49 | 6 years | |
| Sally Jackson | F | - | 23 years | |
| Rodrigo Ruiz Soto | M | - | 7 years | |
| Timothy Woodthorpe | M | - | 24 years | |
| Graham Rivers | M | - | 26 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ian Maurice Gray Prosser | M | 81 | 9 years | |
| Michael Ross | M | 75 | 4 years | |
| Liam Ratcliffe | M | 60 | 2 years | |
| Jean-Pierre Garnier | M | 75 | 8 years | |
| Julian Heslop | M | 70 | 13 years | |
| Peter Traber | M | 69 | 3 years | |
| John David Coombe | M | 79 | 5 years | |
| Murray Stewart | M | 63 | 17 years | |
| Robin M. Young | M | 57 | 7 years | |
| John Lepore | M | - | 15 years | |
| Thierry Loriot | M | - | - | |
| Roger Connor | M | - | 24 years | |
| Michael Owen | M | 73 | 9 years | |
| Sjoerd Wadman | M | - | 12 years | |
| Arthur Levin | M | 70 |
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | 2 years |
| David Wheadon | M | 66 | 5 years | |
| Lawson Macartney | M | 66 | 12 years | |
| Denis Brodsky | M | 53 | 5 years | |
| Robert J. DiVasto | M | 68 | 2 years | |
| Steven Gelone | M | 56 | 2 years | |
| Scott Fields | M | 69 | 5 years | |
| Edward Littler | M | - | - | |
| Marie Paule Richard | M | 72 | 1 years | |
| David Rodman | M | 69 |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | - |
| Aimee L. Jackson | M | - |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | - |
| Stephen Ruddy | M | 60 | - | |
| Julie VanOrsdel Daves | F | - |
miRagen Therapeutics, Inc. /Old/
miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | 2 years |
| Clare Khan | M | 72 | 11 years | |
| Melissa Beelen | F | - | 12 years | |
| David Rowe | M | 57 | 20 years | |
| Edgar Cale | M | 60 | 21 years | |
| Jon Ellis | M | 57 | 21 years | |
| Daniel G. Marquess | M | 55 | 4 years | |
| Eddie J. Gray | M | 64 | 12 years | |
| Steve Damment | M | - | 17 years | |
| Oliver Rosen | M | 59 | 4 years | |
| Vivid Sehgal | M | 56 | 6 years | |
| Brian Blakey | M | 61 | 6 years | |
| Dean Hakanson | M | 72 | 7 years | |
| Caroline Chevalier | F | - | 3 years | |
| Anthony S. Murabito | M | - | 19 years | |
| Douglas B. Snyder | M | 60 | 6 years | |
| Franco di Muzio | M | - | 8 years | |
| Ursula B. Bartels | F | 66 | 11 years | |
| Ronaldo Hermann Schmitz | M | 85 | 9 years | |
| Michael D. Rogers | M | 68 | 6 years | |
| Eric Carter | M | 72 | - | |
| Peter Goodfellow | M | 72 | 8 years | |
| J. Michael Hamilton | M | 75 | 5 years | |
| Christopher Chipman | M | 50 | 2 years | |
| James R. Beery | M | 83 | 1 years | |
| Tamar Howson | F | 75 | 9 years | |
| Robert Ruffolo | M | 74 | 16 years | |
| Tim Tyson | M | 71 | 6 years | |
| John Apeler Keller | M | 60 | - | |
| Dean Mitchell | M | 68 | 15 years | |
| Roger L. Hawley | M | 71 | 14 years | |
| Joseph Schachle | M | 59 | 3 years | |
| George Poste | M | 79 | 7 years | |
| Martin Rosenberg | M | 78 | 5 years | |
| Robert G. Pietrusko | M | 76 | 1 years | |
| Adrian Rawcliffe | M | 52 | 17 years | |
| Luc Mainville | M | 60 |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | 3 years |
| Margaret Dalesandro | M | 77 | 2 years | |
| Peter Strong | M | - | 3 years | |
| David Lawrence | M | 61 | 13 years | |
| Rupert Bondy | M | 62 | - | |
| Ford Calhoun | M | - | - | |
| Lisa Porter | M | 60 | 5 years | |
| Lucy Shapiro | M | 83 | 5 years | |
| Michael V. Milburn | M | - | 10 years | |
| Elaine Jones | M | 69 | - | |
| Gary Patou | M | 65 | 5 years | |
| Argeris Karabelas | M | 71 | 6 years | |
| Paul Magrez | M | - | 4 years | |
| Ian Gilham | M | 64 | - | |
| Wissam Al-Adani | M | 50 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 70 | 78.65% |
| United States | 18 | 20.22% |
| Canada | 1 | 1.12% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Christopher J. Morl
- Personal Network
